A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
NCT04171700
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
83
Enrollment
INDUSTRY
Sponsor class
Stopped
The study was terminated due to a change in development priorities.
Conditions
Solid Tumor
Interventions
DRUG:
Rucaparib
Sponsor
pharmaand GmbH